Gathering the record
Relay is organizing the evidence and source boundaries.
Long-acting glucagon / GLP-1 dual receptor agonist
An experimental drug being studied for weight loss and a form of fatty-liver disease called MASH.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
A published 725-participant Phase 3 obesity trial plus randomized Phase 2 obesity, type 2 diabetes, and biopsy-confirmed MASH studies.
It combines appetite and glucose-related GLP-1 signaling with glucagon-receptor activity relevant to hepatic and energy metabolism.
The treatment-regimen estimand showed about 12–13% mean reduction versus 5.4% with placebo.
This is direct human liver evidence, not merely an inference from weight loss.
The short Phase 2 study supports biological activity in diabetes but not an approved treatment claim.
Maximum weight-loss estimates should be read alongside how many participants tolerated and completed treatment.
Phase 3 publication is not the same as regulatory approval.
Risks & unknowns
Gastrointestinal adverse events and treatment discontinuation materially affect interpretation of survodutide efficacy.
Controlled human evidenceCross-trial tolerability comparisons are unreliable because escalation schedules and populations differ.
Open sourceThe available information does not reliably show how often particular side effects occur.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Gastrointestinal adverse events and treatment discontinuation materially affect interpretation of survodutide efficacy.
Controlled human evidenceStudy discontinuation describes what happened under a study protocol; it is not an emergency-action threshold.
Open sourceRelay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational; Phase 3 obesity and MASH development Long-term cardiovascular and renal outcomes, rare-event safety, durability after discontinuation, and whether ongoing Phase 3 MASH trials confirm histologic benefit.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
A 76-week Phase 3 trial studied adults with obesity or overweight without diabetes.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| 76 weeks | 3.6 or 6 mg targets | Once weekly |
These are adjusted target amounts, not starting doses. A complete escalation schedule is not established by the abstract and is not inferred here.
Survodutide · SYNCHRONIZE-1 Phase 3 trial Primary article · Methods / interventionThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A published Phase 3 trial evaluated survodutide in adults with obesity or overweight who did not have type 2 diabetes.
Population: Adults with obesity or overweight without type 2 diabetes
Design: Randomized, double-blind, placebo-controlled 76-week trial
Mechanisms
Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist designed with GLP-1-biased activity. In the 725-participant SYNCHRONIZE-1 Phase 3 trial, treatment-regimen mean weight change at 76 weeks was −12.2% and −13.0% for the two studied doses versus −5.4% with placebo; efficacy-estimand values reached −15.3% and −16.6%. Earlier controlled studies demonstrated dose-dependent weight and HbA1c reductions, and a biopsy-based Phase 2 MASH trial showed significantly more MASH improvement without worsening fibrosis than placebo. Gastrointestinal adverse events and treatment discontinuation are important tolerability boundaries. Cardiovascular, renal, long-term safety, and pivotal MASH outcomes remain under study.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Published Phase 3 obesity and controlled Phase 2 metabolic and biopsy-based MASH evidence are available.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Findings are substantial; approval, long-term outcomes, and pivotal MASH confirmation remain pending.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The trial population, escalation procedures, and 76-week outcomes cannot be converted into one transferable schedule. The study does not establish approval, long-term cardiovascular outcomes, or equivalence to independently sourced material. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized, double-blind, placebo-controlled 76-week trial
Adults with obesity or overweight without type 2 diabetes
Treatment-regimen mean weight change was −12.2% and −13.0% versus −5.4% with placebo; efficacy-estimand reductions reached −15.3% and −16.6%.
Study administration: Once-weekly survodutide 3.6 mg, 6.0 mg, or placebo under trial protocols
Limitations: The placebo group lost substantial weight, treatment completion was incomplete, gastrointestinal events were common, and long-term outcomes were not established.
Randomized, double-blind, placebo-controlled biopsy study
Adults with biopsy-confirmed MASH and fibrosis
A significantly larger proportion of survodutide-treated participants met the primary MASH-improvement endpoint than placebo.
Study administration: Once-weekly survodutide dose groups or placebo
Limitations: The study was Phase 2, not powered to establish clinical liver outcomes, and fibrosis improvement requires confirmation in larger longer trials.
Randomized, double-blind, placebo-controlled dose-finding trial
Adults with overweight or obesity
Survodutide produced dose-dependent weight reduction versus placebo, with gastrointestinal adverse events and discontinuations affecting interpretation.
Study administration: Multiple once-weekly survodutide dose-escalation regimens or placebo
Limitations: Phase 2 duration and dose-escalation tolerability do not establish long-term benefit-risk or an approved regimen.
Randomized dose-response trial with placebo and open-label semaglutide context
Adults with type 2 diabetes
Survodutide reduced HbA1c and body weight over 16 weeks in a dose-dependent pattern.
Study administration: Multiple survodutide regimens, placebo, and open-label semaglutide
Limitations: Short duration and an open-label active comparator do not establish long-term comparative effectiveness.
Randomized clinical-outcomes development program
Adults with MASH and moderate or advanced fibrosis
LIVERAGE is evaluating whether the Phase 2 histology signal translates into a pivotal Phase 3 benefit.
Study administration: Survodutide or placebo
Limitations: No completed outcome results were available at the evidence cutoff.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-06-07 · PMID 42253238 · DOI 10.1056/NEJMoa2600751
2024-10-10 · NCT06632444
2024-06-07 · PMID 38847460
2024-02-01 · PMID 38330987
2024-01-01 · PMID 38095657
2023-10-10 · NCT06066515